Tanya B. Dorff, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on STAMPEDE and a Phase IV Trial

0 seconds of 0 secondsVolume 90%

00:00

Tanya B. Dorff, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on STAMPEDE and a Phase IV Trial

2017 ASCO Annual Meeting

Tanya B. Dorff, MD, of the USC Norris Comprehensive Cancer Center, and Sumanta K. Pal, MD, of the City of Hope, discuss two key presentations on prostate cancer: findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy, and an after-market study on continuing enzalutamide post PSA progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstracts LBA5003, 5004)

Dean F. Bajorin, MD, and Peter H. O’Donnell, MD, on Urothelial Cancer: Results From Two KEYNOTE Trials

Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, and Peter H. O’Donnell, MD, of The University of Chicago Medical Center, discuss their study findings on treating advanced urothelial cancer with pembrolizumab, paclitaxel, docetaxel, or vinflunine. (Abstracts 4501 and 4502)

Prostate Cancer

Gerhardt Attard, MD, PhD, on Prostate Cancer: Results From an After-Market Study on Enzalutamide

Gerhardt Attard, MD, PhD, of The Royal Marsden Hospital and The Institute of Cancer Research, discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstract 5004)

Lung Cancer

Today In Oncology

Tanya B. Dorff, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on STAMPEDE and a Phase IV Trial

Related Videos

Dean F. Bajorin, MD, and Peter H. O’Donnell, MD, on Urothelial Cancer: Results From Two KEYNOTE Trials

Gerhardt Attard, MD, PhD, on Prostate Cancer: Results From an After-Market Study on Enzalutamide

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial

Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the ICON6 Trial

Taofeek K. Owonikoko, MD, PhD, on SCLC: Results of the ECOG-ACRIN 2511 Trial

Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction

Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings

Comparing Biopsy Techniques for Prostate Cancer Detection

Characteristics of Nasopharyngeal Carcinoma in the United States

Grocery Store Choice Could Impact Obesity Related Cancer Mortality